The expansion is a result of strong traction and effective results from Zyla’s digital treatment solution among cardiometabolic patients
Zyla Health has declared its strategic growth in new geographies in Southeast Asia after a successful regional launch in 2024. The expansion is a result of strong traction and effective results from Zyla’s digital treatment solution among cardiometabolic patients.
Hundreds of Southeast Asian doctors now prescribe Zyla’s AI-based solution to hypertension, diabetes, dyslipidemia, chronic heart failure, and comorbid conditions patients. The outcome: enhanced healthcare results, higher patient activation, and a quantifiable change in everyday health habits.
Khushboo Aggarwal, CEO, Zyla Health, said, “Our mission is to deliver high-quality, personalised care to the farthest reaches of the globe. The initial success we have achieved in Southeast Asia demonstrates that with the right combination of technology, medical knowledge, and local customisation, we can facilitate meaningful and sustainable health outcomes worldwide. We are thrilled to now extend this revolutionary care model to even more parts of Southeast Asia.”
